restoril side effects depression

In a recent study posted to the medRxiv* preprint server, researchers assessed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies in Chile.

Study: SARS-CoV-2 neutralizing antibodies in Chile after a vaccination campaign with five different schemes. Image Credit: Corona Borealis Studio/Shutterstock

The waning protection from natural as well as coronavirus disease 2019 (COVID-19) vaccine-induced immunity has worsened the morbidity and mortality caused by the pandemic. This has given rise to increased disease susceptibility and public outbreaks.

About the study

In the present study, researchers compared the various COVID-19 vaccination schemes in Chile according to the levels of SARS-CoV-2 neutralizing antibodies (nAbs).

The team measured the neutralization capacity in human serological samples by employing pseudotyped vesicular stomatitis virus (VSV) having a sequence that encoded for enhanced green fluorescent protein (GFP) that served as a reporter gene forming the VSV-GFP-Spike SARS-CoV-2 Wuhan strain. The samples analyzed in the study were collected from persons who were enrolled in a SARS-CoV-2 seroprevalence study.

A total of 2,198 serum samples were collected from individuals aged seven years and above in November 2021. Six distinct cohorts of SARS-CoV-2 positive samples were formed based on the reported history of natural infection using five vaccination schemes that were used most frequently, which included two CoronaVac (CC), two Pfizer (PP), how to eat dabur triphala churna CC followed by one Oxford AstraZeneca (CCO), CC followed by one Pfizer (CCP), and three Pfizer (PPP) vaccines. The team randomly selected 20 persons from each of the six groups.

The level of nAb response was evaluated according to the inhibitory concentration wherein 50% of the viral entry was inhibited (IC50). This IC50 was estimated for each serum sample by estimating the observed GFP fluorescence which showed the amount of VSV-GFP-Spike SARS-CoV-2 pseudotype viral entrance.     

Results

The study results showed that 97.3% of the total serum samples analyzed were seropositive. Approximately, 82.5% of samples exhibited a nAb response while no significant differences were observed based on gender and age. Notably, the nAb levels were substantially higher in people who were non-smokers and in those who had received their COVID-19 booster vaccine doses. The nAb levels showed considerable variation as per the vaccination scheme used. 

The team also observed that with respect to the nAb levels, the cohort displaying only a basal immunization scheme had nAb levels that were comparable to those in naturally infected patients. However, individuals who had received their COVID-19 booster vaccine showed nAb levels that were significantly higher than those in the primary vaccinated and the naturally infected individuals.

Furthermore, the team observed that PPP administration showed the highest median response of nAb, while no substantial distinctions were found post the administration of the CCP scheme. Moreover, the nAb response was notably higher than those in the CCO recipients. The team also found that the three booster vaccination schemes resulted in levels of nAbs that were remarkably higher than those in the naturally infected and the CC and PP-administered groups.

Among the basal vaccination schemes such as CC and PP administrations, substantially higher levels of nAbs were observed for the PP scheme than for the CC scheme. The team also found a waning of antibody titers for groups vaccinated with the basal schemes but not for the booster-vaccinated groups.                                       

Overall, the study findings showed that the COVID-19 booster vaccine dose substantially increased anti-SARS-CoV-2 nAb levels, irrespective of the vaccination scheme or the nAb levels induced by natural infection.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
  • Ximena Aguilera, et al. (2022). SARS-CoV-2 neutralizing antibodies in Chile after a vaccination campaign with five different schemes. medRxivdoi: https://doi.org/10.1101/2022.05.03.22274622 https://www.medrxiv.org/content/10.1101/2022.05.03.22274622v1

Posted in: Medical Science News | Medical Research News | Disease/Infection News

Tags: Antibodies, Antibody, Coronavirus, Coronavirus Disease COVID-19, covid-19, Fluorescence, Fluorescent Protein, Gene, immunity, Immunization, Mortality, Pandemic, Protein, Reporter Gene, Respiratory, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Stomatitis, Syndrome, Vaccine, Virus

Comments (0)

Written by

Bhavana Kunkalikar

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

Source: Read Full Article